MX370397B - Vacuna para enfermedad intrauterina. - Google Patents

Vacuna para enfermedad intrauterina.

Info

Publication number
MX370397B
MX370397B MX2015006862A MX2015006862A MX370397B MX 370397 B MX370397 B MX 370397B MX 2015006862 A MX2015006862 A MX 2015006862A MX 2015006862 A MX2015006862 A MX 2015006862A MX 370397 B MX370397 B MX 370397B
Authority
MX
Mexico
Prior art keywords
compositions
pyogenes
whole cells
necrophorum
coli
Prior art date
Application number
MX2015006862A
Other languages
English (en)
Other versions
MX2015006862A (es
Inventor
Carvalho Bicalho Rodrigo
Owen Gilbert Robert
Machado Vinicius
Bicalho Marcela
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of MX2015006862A publication Critical patent/MX2015006862A/es
Publication of MX370397B publication Critical patent/MX370397B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/114—Fusobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a una composición veterinaria para usarse para la profilaxis de metritis puerperal en un rumiante, en donde la composición veterinaria está formulada para ser administrable por vía subcutánea al mamífero rumiante, la composición veterinaria comprende la proteína leucotoxina (LKT) de F. necrophorum, la proteína adhesina fimbrial (FimH) de E.coli tipo 1, y la proteína piolisina de T.pyogenes (PLO).
MX2015006862A 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina. MX370397B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731333P 2012-11-29 2012-11-29
PCT/US2013/063866 WO2014084964A1 (en) 2012-11-29 2013-10-08 Vaccine for intrauterine disease

Publications (2)

Publication Number Publication Date
MX2015006862A MX2015006862A (es) 2016-06-29
MX370397B true MX370397B (es) 2019-12-11

Family

ID=50828340

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006862A MX370397B (es) 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina.
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Country Status (12)

Country Link
US (4) US9533034B2 (es)
EP (2) EP2925353B1 (es)
JP (1) JP6301945B2 (es)
AU (1) AU2013353403B2 (es)
BR (3) BR112015012288B1 (es)
CA (1) CA2893072C (es)
ES (1) ES2718491T3 (es)
HU (1) HUE043129T2 (es)
MX (2) MX370397B (es)
NZ (2) NZ708669A (es)
RU (1) RU2672589C2 (es)
WO (1) WO2014084964A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015012288B1 (pt) * 2012-11-29 2022-07-26 Cornell University Uso de uma composição veterinária
MX380387B (es) 2015-03-12 2025-03-12 Zoetis Services Llc Metodos de piolisina y composiciones.
BR112018009319A8 (pt) * 2015-11-09 2019-02-26 Epitopix Llc polipeptídeos de fusobacterium e métodos de uso
KR102474924B1 (ko) 2020-04-22 2022-12-06 영남대학교 산학협력단 대장균 부착 단백질 FimH를 유효성분으로 포함하는 항암 면역 증강용 조성물
WO2025093740A1 (en) 2023-11-03 2025-05-08 Intervet International B.V. Recombinant pyolysin protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2186694T3 (es) * 1990-06-07 2003-05-16 Bayer Ag Vacuna bacteriana para el tratamiento de necrosis hepatica causada por f. necrophorum.
CA2138778C (en) 1992-06-26 2003-03-11 Tiruvoor G. Nagaraja Fusobacterium necrophorum leukotoxoid vaccine
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
WO1996040237A1 (en) 1995-06-07 1996-12-19 Kansas State University Research Foundation Actinomyces pyogenes and actinomyces pyogenes/fusobacterium necrophorum vaccines for immunizing cattle and sheep
US6669940B2 (en) * 2000-04-25 2003-12-30 Kansas University Research Foundation Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
MY146351A (en) * 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
BR112015012288B1 (pt) * 2012-11-29 2022-07-26 Cornell University Uso de uma composição veterinária

Also Published As

Publication number Publication date
NZ754388A (en) 2022-05-27
EP2925353A1 (en) 2015-10-07
AU2013353403B2 (en) 2018-04-19
US9533034B2 (en) 2017-01-03
AU2013353403A1 (en) 2015-07-02
US10821169B2 (en) 2020-11-03
EP3545970A1 (en) 2019-10-02
HUE043129T2 (hu) 2019-08-28
US20180236055A1 (en) 2018-08-23
JP2016507479A (ja) 2016-03-10
EP2925353A4 (en) 2016-08-10
CA2893072A1 (en) 2014-06-05
US9981032B2 (en) 2018-05-29
BR122019025365B1 (pt) 2022-07-26
WO2014084964A1 (en) 2014-06-05
US20170100473A1 (en) 2017-04-13
RU2015125646A (ru) 2017-01-10
US20150335725A1 (en) 2015-11-26
US20190358311A1 (en) 2019-11-28
CA2893072C (en) 2023-10-03
RU2672589C2 (ru) 2018-11-16
ES2718491T3 (es) 2019-07-02
BR112015012288A2 (pt) 2018-02-06
BR112015012288B1 (pt) 2022-07-26
NZ708669A (en) 2019-12-20
MX2019012044A (es) 2020-01-13
MX2015006862A (es) 2016-06-29
JP6301945B2 (ja) 2018-03-28
BR122019025362B1 (pt) 2022-07-26
EP2925353B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MY187047A (en) Selective pyy compounds and uses thereof
MX2019012044A (es) Vacuna para enfermedad intrauterina.
PH12018500284B1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EP4378962A3 (en) Anti-cancer fusion polypeptide
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
CR20200408A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IN2015DN02729A (es)
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
SG10201811574YA (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
PH12014501991B1 (en) Phenicol antibacterials
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2020005235A (es) Celula humana transformada y uso de la misma.
PH12015502556A1 (en) Modified release formulation
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos

Legal Events

Date Code Title Description
FG Grant or registration